Cargando…

Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients

To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed–time-point 2-(18)F-fluoro-2-deoxy-d-glucose-positron emission tomography ((18)F-FDG-PET) performs better than standard–time-point (18)F-FDG-PET. MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayerhoefer, Marius E., Giraudo, Chiara, Senn, Daniela, Hartenbach, Markus, Weber, Michael, Rausch, Ivo, Kiesewetter, Barbara, Herold, Christian J., Hacker, Marcus, Pones, Matthias, Simonitsch-Klupp, Ingrid, Müllauer, Leonhard, Dolak, Werner, Lukas, Julius, Raderer, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703065/
https://www.ncbi.nlm.nih.gov/pubmed/26402137
http://dx.doi.org/10.1097/RLU.0000000000001005
Descripción
Sumario:To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed–time-point 2-(18)F-fluoro-2-deoxy-d-glucose-positron emission tomography ((18)F-FDG-PET) performs better than standard–time-point (18)F-FDG-PET. MATERIALS AND METHODS: Patients with untreated histologically verified MALT lymphoma, who were undergoing pretherapeutic (18)F-FDG-PET/computed tomography (CT) and consecutive (18)F-FDG-PET/magnetic resonance imaging (MRI), using a single (18)F-FDG injection, in the course of a larger-scale prospective trial, were included. Region-based sensitivity and specificity, and patient-based sensitivity of the respective (18)F-FDG-PET scans at time points 1 (45–60 minutes after tracer injection, TP1) and 2 (100–150 minutes after tracer injection, TP2), relative to the reference standard, were calculated. Lesion-to-liver and lesion-to-blood SUV(max) (maximum standardized uptake values) ratios were also assessed. RESULTS: (18)F-FDG-PET at TP1 was true positive in 15 o f 23 involved regions, and (18)F-FDG-PET at TP2 was true-positive in 20 of 23 involved regions; no false-positive regions were noted. Accordingly, region-based sensitivities and specificities were 65.2% (confidence interval [CI], 45.73%–84.67%) and 100% (CI, 100%-100%) for (18)F-FDG-PET at TP1; and 87.0% (CI, 73.26%–100%) and 100% (CI, 100%-100%) for (18)F-FDG-PET at TP2, respectively. FDG-PET at TP1 detected lymphoma in at least one nodal or extranodal region in 7 of 13 patients, and (18)F-FDG-PET at TP2 in 10 of 13 patients; accordingly, patient-based sensitivity was 53.8% (CI, 26.7%–80.9%) for (18)F-FDG-PET at TP1, and 76.9% (CI, 54.0%–99.8%) for (18)F-FDG-PET at TP2. Lesion-to-liver and lesion-to-blood maximum standardized uptake value ratios were significantly lower at TP1 (ratios, 1.05 ± 0.40 and 1.52 ± 0.62) than at TP2 (ratios, 1.67 ± 0.74 and 2.56 ± 1.10; P = 0.003 and P = 0.001). CONCLUSIONS: Delayed–time-point imaging may improve (18)F-FDG-PET in MALT lymphoma.